Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay)
CD154; TRAP; HIGM1; IGM; IMD3; TBAM; T-BAM; TNFSF5; Gp39; TNF Superfamily Member 5; Hyper-IgM Syndrome; TNF-Related Activation Protein; T-Cell B-Cell Activating Molecule
(Note: Up to 8-plex in one testing reaction)
- Product No.LMA119Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.98-1000pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.327 pg/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 405
US$ 420
US$ 443
US$ 475
US$ 506
US$ 552
US$ 622
Result
For more details, please contact local distributors! US$ 778 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 80-101 | 90 |
EDTA plasma(n=5) | 79-92 | 83 |
heparin plasma(n=5) | 93-101 | 96 |
sodium citrate plasma(n=5) | 88-96 | 91 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 80-93% | 84-104% | 94-102% | 83-90% |
EDTA plasma(n=5) | 90-101% | 91-101% | 96-105% | 78-95% |
heparin plasma(n=5) | 89-98% | 79-102% | 87-101% | 94-102% |
sodium citrate plasma(n=5) | 78-101% | 80-94% | 93-105% | 89-102% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:CD40L) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation PubMed: 22899170 |
Molecules | The Protective Effects of Alisol A 24-Acetate from Alisma canaliculatum on Ovariectomy Induced Bone Loss in Vivo Pubmed:26760992 |
Journal of Neuroinflammation | Th17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. pubmed:28114998 |
BMC Nephrology | Renal effects of metallothionein induction by zinc in vitro and in vivo pubmed:28302075 |
Toxicology and Applied Pharmacology | Effects of diisononyl phthalate on osteopenia in intact mice pubmed:28893586 |
INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation Pubmed: 30857843 |
Available at SSRN 3335365 | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers |
Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation |
journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers Pubmed: 32812629 |
Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices Pubmed: 31838449 |
Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study Pubmed: 32085544 |
Persistently higher serum sCD40L levels are associated with mortality in septic patients | |
Journal of Orthopaedic Translation | Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-¦ÊB and MAPK activation 33981577 |
Bioactive Materials | Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy 34820587 |
Catalog No. | Related products for research use of Mus musculus (Mouse) Organism species | Applications (RESEARCH USE ONLY!) |
RPA119Mu02 | Recombinant Cluster Of Differentiation 40 Ligand (CD40L) | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA119Mu01 | Recombinant Cluster Of Differentiation 40 Ligand (CD40L) | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA119Mu01 | Polyclonal Antibody to Cluster Of Differentiation 40 Ligand (CD40L) | WB; IHC; ICC; IP. |
PAA119Mu02 | Polyclonal Antibody to Cluster Of Differentiation 40 Ligand (CD40L) | WB; IHC; ICC; IP. |
SEA119Mu | ELISA Kit for Cluster Of Differentiation 40 Ligand (CD40L) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA119Mu | Multiplex Assay Kit for Cluster Of Differentiation 40 Ligand (CD40L) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |